PTC Therapeutics, Inc.
PTCT
$71.70
-$0.27-0.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 101.55% | -76.83% | -22.75% | 7.23% | -4.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.55% | -76.83% | -22.75% | 7.23% | -4.19% |
| Cost of Revenue | -4.29% | 6.46% | -0.69% | -32.70% | -15.77% |
| Gross Profit | 343.31% | -86.45% | -65.89% | 287.62% | 39.63% |
| SG&A Expenses | -5.43% | 6.45% | 14.40% | 14.42% | 22.68% |
| Depreciation & Amortization | 191.58% | 204.92% | 182.70% | 148.16% | 41.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.03% | 10.10% | 7.53% | -16.58% | -2.88% |
| Operating Income | 527.38% | -95.35% | -414.30% | 106.71% | -4.50% |
| Income Before Tax | 237.29% | -100.26% | -46.87% | 76.45% | 17.12% |
| Income Tax Expenses | 326.49% | -99.45% | 85.71% | -549.84% | -146.13% |
| Earnings from Continuing Operations | 228.75% | -100.32% | -104.85% | 114.90% | 34.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 228.75% | -100.32% | -104.85% | 114.90% | 34.61% |
| EBIT | 527.38% | -95.35% | -414.30% | 106.71% | -4.50% |
| EBITDA | 704.40% | -93.81% | -654.61% | 132.10% | -3.55% |
| EPS Basic | 221.22% | -100.31% | -95.99% | 114.61% | 35.81% |
| Normalized Basic EPS | 233.94% | -100.36% | -426.26% | 69.23% | 7.71% |
| EPS Diluted | 210.58% | -100.34% | -95.99% | 114.04% | 35.79% |
| Normalized Diluted EPS | 220.81% | -100.40% | -426.26% | 72.28% | 7.71% |
| Average Basic Shares Outstanding | 6.21% | 5.64% | 4.52% | 2.01% | 1.86% |
| Average Diluted Shares Outstanding | 17.75% | -4.47% | 4.52% | 13.25% | 1.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |